Canada: Is Clinical Trial Data In The Possession Of Health Canada Confidential? Not Quite, Says The Federal Court.

Last Updated: October 12 2018
Article by CyberLex Blog, Eric Pellegrino and Bruna D. Kalinoski

Most Read Contributor in Canada, September 2018

On July 9, 2018, the Federal Court released its decision ordering Health Canada to provide the results of certain clinical trials, including participant level datasets, to an American researcher: Doshi v Canada (Attorney General), 2018 FC 710. Health Canada requires researchers to sign a standard confidentiality agreement in order to release clinical trial data for the purpose of research. On the basis of the researcher's refusal to sign the standard confidentiality agreement, Health Canada unsuccessfully attempted to keep confidential the requested reams of clinical trial data.


Clinical trials of new drug development processes are subject to domestic and international regulatory frameworks. In Canada, the Foods and Drugs Act and the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) grants the Minister of Health discretion to disclose information concerning drugs when "the purpose of disclosure is related to the protection and promotion of human health or safety of the public" and such disclosure is made to "a person who carries out functions relating to the protection or promotion of human health or the safety of the public" (section 21.1(3)(c)). International counterparts that apply to practices of the pharmaceutical industry are the North American Free Trade Agreement (NAFTA; Article 1711) and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS; Article 3). The above data protection framework – the validity of which has been upheld by the Federal Court of Appeal in Apotex Inc. v Canada (Health), 2010 FCA 334 – provides important safeguards for the information generated by innovator pharmaceutical companies.

Clinical trials are usually conducted by researchers under a confidentiality agreement with pharmaceutical companies. Health Canada, upon assessing clinical trial results submitted with a new drug submission (NDS), issues a notice of compliance (NOC) authorizing the new drug to enter the market. Pharmaceutical companies have maintained that clinical trials datasets in possession of the regulator constitute confidential business information that should not be made public.

Facts and Judicial Review Application

Dr. Doshi, an Assistant Professor at the University of Maryland, sought judicial review of an order of mandamus requiring the Minister of Health to release clinical trial data which Health Canada had received from the makers of HPV vaccines Gardasil, Gardasil 9, and Cervarix, as well as the anti-viral influenza, and the medications Tamiflu and Relenza (para 91).

Dr. Doshi had applied to Health Canada for access to "complete copies of all sections of all clinical study reports", as well as "all electronic datasets from these same trials, including participant level datasets" (para 22). He claimed that the information was needed for a systematic review. Health Canada claimed that the data was confidential business information that could only be communicated upon the signing of a confidentiality agreement. Dr. Doshi opposed the confidentiality terms and, instead of signing the agreement, advanced in his judicial review that: (1) Health Canada's refusal had no basis in law; and (2) the confidentiality agreement would be a hindrance to his ability to conduct the research project and publish results.

At issue was the interpretation of subsection 21.1(3) of the Protecting Canadians from Unsafe Drugs Act ("Vanessa's Law"). The case is interesting not only because it was the first time the court was called upon to apply Vanessa's Law, but also because the court was required to decide other important ancillary issues, such as the confidential nature of clinical trial data and the bearing such nature may have on freedom of expression under section 2(b) of the Canadian Charter of Rights and Freedoms.


In light of administrative law principles concerning the exercise of discretionary powers, Justice Grammond held that it was unreasonable for Health Canada to impose a confidentiality requirement as a condition for the disclosure of the data requested by Dr. Doshi (para 87).

(1) Statutory purpose

Vanessa's Law amended the Food and Drugs Act to add subsection 21.1(3), permitting the Minister of Health to disclose confidential business information about a therapeutic product in circumstances such as those presented by the applicant, that is, for use in academic research. The Court found that Health Canada exercised the powers granted by Vanessa's Law in a way that disregarded its legislative purpose, namely, to improve clinical trial transparency (para 75).

(2) Improper "fettering" of discretion

The Court held that Health Canada improperly fettered its discretion in light of the express authorization to disclose data pursuant to subsection 21.1(3). The regulations imply that, in effect, "there is no legitimate interest in keeping the results of clinical trials private" in those circumstances (para 82). Health Canada accepted that Dr. Doshi was "a person who carries out functions relating to the protection or promotion of human health or the safety of the public" and that disclosure would be "related to the protection or promotion of human health or the safety of the public," as required under section 21.1(3). Accordingly, by imposing the confidentiality agreement, Health Canada read words in the legislation which were not intended by the government (para 81).

(3) Breach of the Canadian Charter of Rights and Freedoms

The Court held that the confidentiality agreement would prevent Dr. Doshi from drawing on the clinical trial reports and publishing his research results based on such reports. The Court further stated that "[f]reedom of expression certainly includes freedom to disseminate research results" (paras 83-84), and that the restriction imposed by Health Canada was without justification in light of the statutory purpose to improve clinical trial transparency. As a result, in these circumstances, the confidentiality agreement would be incompatible with Dr. Doshi's freedom of expression under section 2(b) of the Canadian Charter of Rights and Freedoms.


  1. Justice Grammond noted that public disclosure of trial results may prevent biased testing, selective publishing, regulatory failures, and questionable conclusions on the reliability of drugs. Justice Grammond also noted that "[t]he scheme of the legislation is that certain categories of information, defined by regulations, would be made public, but that other categories would still be described as 'confidential business information'". Accordingly, the court did not decide that a confidentiality agreement is always inappropriate, as "[t]here will be situations where Health Canada may validly impose a confidentiality requirement with respect to specific categories of information, but that decision must be made on a case-by-case basis" (para 74).
  2. Importantly, Justice Grammond also stated that nothing in the Court's reasons was intended to lessen the protection of privacy and anonymity of clinical trial participants, since research ethics and guidelines warrant research participant anonymity.
  3. Finally, it was noted that, while disclosure of information in the possession of Health Canada could also be requested under the Access of Information Act, RSC 1985, c A-1, the Act requires that notice be given to the third party who may oppose disclosure invoking section 20 of the Act, which covers confidential scientific or technical information. As a result, litigation concerning the Act may be costly, lengthy and ineffective to ensure clinical trial transparency (para 14).

Following the Federal Court decision, Health Canada indicated that it is working on regulations to publicly release a large amount of information in clinical trial reports for a wide range of medications. Stakeholders should watch out for new developments on this front.

To view the original article click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions